

# Johan A Maertens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9219888/publications.pdf>

Version: 2024-02-01

156  
papers

19,930  
citations

38660

50  
h-index

11030

137  
g-index

161  
all docs

161  
docs citations

161  
times ranked

13938  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). <i>Haematologica</i> , 2023, 108, 22-33.	1.7	15
2	Lung microbiota predict invasive pulmonary aspergillosis and its outcome in immunocompromised patients. <i>Thorax</i> , 2022, 77, 283-291.	2.7	19
3	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology. <i>Clinical Microbiology and Infection</i> , 2022, 28, 580-587.	2.8	133
4	Toxoplasmosis after allogeneic haematopoietic cell transplantation: experience using a PCR-guided pre-emptive approach. <i>Clinical Microbiology and Infection</i> , 2022, 28, 440-445.	2.8	5
5	Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106472.	1.1	7
6	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2022, 6, 2427-2433.	2.5	46
7	Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping. <i>American Journal of Hematology</i> , 2022, 97, 548-561.	2.0	36
8	Molecular characterization of mutant <i>TP53</i> acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood</i> , 2022, 139, 2347-2354.	0.6	131
9	Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1003-1009.	2.8	8
10	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). <i>Leukemia</i> , 2022, 36, 1215-1226.	3.3	19
11	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). <i>Leukemia</i> , 2022, 36, 1467-1480.	3.3	63
12	MAVS Expression in Alveolar Macrophages Is Essential for Host Resistance against <i>Aspergillus fumigatus</i> . <i>Journal of Immunology</i> , 2022, 209, 346-353.	0.4	5
13	Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature. <i>Acta Clinica Belgica</i> , 2021, 76, 500-508.	0.5	15
14	Prospective Evaluation of the Turbidimetric $\beta$ -D-Glucan Assay and 2 Lateral Flow Assays on Serum in Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2021, 72, 1577-1584.	2.9	24
15	A rare case of invasive pulmonary aspergillosis presenting as organizing pneumonia due to <i>Aspergillus niger</i> in an immunocompetent host. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101503.	0.2	1
16	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. <i>Cancers</i> , 2021, 13, 672.	1.7	7
17	Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. <i>Lancet, The</i> , 2021, 397, 499-509.	6.3	119
18	Defining Galactomannan Positivity in the Updated EORTC/MSGERC Consensus Definitions of Invasive Fungal Diseases. <i>Clinical Infectious Diseases</i> , 2021, 72, S89-S94.	2.9	28

#	ARTICLE	IF	CITATIONS
19	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <i>EClinicalMedicine</i> , 2021, 33, 100787.	3.2	14
20	Triazole-Resistance in Environmental <i>Aspergillus fumigatus</i> in Latin American and African Countries. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 292.	1.5	16
21	Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis. <i>MBio</i> , 2021, 12, e0036921.	1.8	6
22	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. <i>Intensive Care Medicine</i> , 2021, 47, 674-686.	3.9	49
23	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	3.9	106
24	Serum amyloid P component is an essential element of resistance against <i>Aspergillus fumigatus</i> . <i>Nature Communications</i> , 2021, 12, 3739.	5.8	18
25	Diagnosis and treatment of COVID-19 associated pulmonary aspergillosis in critically ill patients: results from a European confederation of medical mycology registry. <i>Intensive Care Medicine</i> , 2021, 47, 1158-1160.	3.9	43
26	Voriconazole pharmacogenetics – Authors' reply. <i>Lancet</i> , The, 2021, 398, 578-579.	6.3	0
27	When to change treatment of acute invasive aspergillosis: an expert viewpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 16-23.	1.3	15
28	Stable prevalence of triazole-resistance in <i>Aspergillus fumigatus</i> complex clinical isolates in a Belgian tertiary care center from 2016 to 2020. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1774-1778.	0.8	6
29	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
30	Ultra-performance liquid chromatography for quantification of amphotericin B plasma concentrations after use of liposomal amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 961-966.	1.3	2
31	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Leukemia</i> , 2021, 35, 3585-3588.	3.3	72
32	Post-Transplantation Cyclophosphamide for Gvhd Prophylaxis in Related and Unrelated Allogeneic Hematopoietic Cell Transplantation: Study from the SFGM-TC Registry. <i>Blood</i> , 2021, 138, 2883-2883.	0.6	0
33	Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Blood</i> , 2021, 138, 2818-2818.	0.6	0
34	Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2021, 138, 3953-3953.	0.6	0
35	Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. <i>Medical Mycology</i> , 2020, 58, 417-424.	0.3	48
36	Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. <i>Medical Mycology</i> , 2020, 58, 444-452.	0.3	50

#	ARTICLE	IF	CITATIONS
37	Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT. <i>Journal of Neurology</i> , 2020, 267, 430-439.	1.8	13
38	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	2.9	1,429
39	Proteome analysis of bronchoalveolar lavage fluids reveals host and fungal proteins highly expressed during invasive pulmonary aspergillosis in mice and humans. <i>Virulence</i> , 2020, 11, 1337-1351.	1.8	8
40	Cefepime therapeutic drug monitoring: Evaluation of agreement between peripheral and central venous blood sampling. <i>Clinica Chimica Acta</i> , 2020, 510, 450-454.	0.5	1
41	Reply to Luppi et al. <i>Clinical Infectious Diseases</i> , 2020, 71, 3266-3266.	2.9	0
42	Variable Correlation between Bronchoalveolar Lavage Fluid Fungal Load and Serum-(1,3)- $\beta$ -D-Glucan in Patients with Pneumocystosis: A Multicenter ECMM Excellence Center Study. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 227.	1.5	12
43	Point of care aspergillus testing in intensive care patients. <i>Critical Care</i> , 2020, 24, 642.	2.5	20
44	Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 4430-4437.	2.5	23
45	Hmg1 Gene Mutation Prevalence in Triazole-Resistant <i>Aspergillus fumigatus</i> Clinical Isolates. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 227.	1.5	12
46	Diagnosis of Invasive Aspergillosis in Intensive Care Unit Patients. <i>Current Fungal Infection Reports</i> , 2020, 14, 166-173.	0.9	2
47	Phagosomal removal of fungal melanin reprograms macrophage metabolism to promote antifungal immunity. <i>Nature Communications</i> , 2020, 11, 2282.	5.8	68
48	Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 539-550.	1.5	12
49	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	3.9	278
50	European confederation of medical mycology expert consultation: An ECMM excellence center initiative. <i>Mycoses</i> , 2020, 63, 566-572.	1.8	8
51	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34); <i>DEK-NUP214</i> shows a favourable outcome when performed in first complete remission. <i>British Journal of Haematology</i> , 2020, 189, 920-925.	1.2	16
52	A Mortality Prediction Rule for Hematology Patients with Invasive Aspergillosis Based on Serum Galactomannan Kinetics. <i>Journal of Clinical Medicine</i> , 2020, 9, 610.	1.0	10
53	ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. <i>Leukemia</i> , 2020, 34, 1907-1923.	3.3	20
54	Reply to Mafacioli and Pasqualotto. <i>Clinical Infectious Diseases</i> , 2020, 71, 2542-2543.	2.9	2

#	ARTICLE	IF	CITATIONS
55	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWPâ€EBMT, EORTCâ€IDG and SEIFEM survey. <i>Mycoses</i> , 2020, 63, 420-429.	1.8	7
56	First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. <i>Blood</i> , 2020, 136, 36-36.	0.6	12
57	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3315-3327.	1.3	30
58	Gliotoxin and bis(methylthio)gliotoxin are not reliable as biomarkers of invasive aspergillosis. <i>Mycoses</i> , 2019, 62, 945-948.	1.8	6
59	Antifungal drugs: What brings the future?. <i>Medical Mycology</i> , 2019, 57, S328-S343.	0.3	141
60	Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. <i>New England Journal of Medicine</i> , 2019, 381, 1136-1147.	13.9	108
61	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). <i>Leukemia</i> , 2019, 33, 844-862.	3.3	131
62	Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2759-2766.	1.3	52
63	Defining standards of CARE for invasive fungal diseases in adult haematology patients: antifungal prophylaxis versus treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii21-ii26.	1.3	4
64	Beta- <sc>d</sc>-Glucan for Diagnosing <i>Pneumocystis</i> Pneumonia: a Direct Comparison between the Wako Î²-Glucan Assay and the Fungitell Assay. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	31
65	Standards of CARE: what is considered â€best practiceâ€™™ for the management of invasive fungal infections? A haematologistâ€™™s and a mycologistâ€™™s perspective. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii3-ii8.	1.3	3
66	An introduction to current standards of CARE in invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii2-ii2.	1.3	1
67	Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI. <i>Blood Advances</i> , 2019, 3, 1950-1960.	2.5	9
68	Serial Detection of Circulating Mucorales DNA in Invasive Mucormycosis: A Retrospective Multicenter Evaluation. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 113.	1.5	32
69	Fungal infections in solid organ transplantation: An update on diagnosis and treatment. <i>Transplantation Reviews</i> , 2019, 33, 77-86.	1.2	34
70	Invasive Fungal Infections. , 2019, , 273-280.		3
71	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <sc>FUN</sc>gal infections Definitions in <sc>ICU</sc> patients (<sc>FUNDICU</sc>) project. <i>Mycoses</i> , 2019, 62, 310-319.	1.8	53
72	Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 720-727.	2.0	47

#	ARTICLE	IF	CITATIONS
73	Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients. <i>Future Microbiology</i> , 2019, 14, 175-184.	1.0	3
74	Diagnosing Invasive Pulmonary Aspergillosis in Hematology Patients: a Retrospective Multicenter Evaluation of a Novel Lateral Flow Device. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	21
75	CD34+CD38 <sup>+</sup> leukemic stem cell frequency to predict outcome in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1102-1112.	3.3	130
76	Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors. <i>Blood</i> , 2019, 134, 1-1.	0.6	47
77	Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation: a Multicenter Prospective Study. <i>Blood</i> , 2019, 134, 37-37.	0.6	2
78	Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors. <i>Blood</i> , 2019, 134, 592-592.	0.6	0
79	Evolution of Clinically Relevant Subclones during Chemotherapy Treatment of ALL As Determined by Single-Cell DNA and RNA Sequencing. <i>Blood</i> , 2019, 134, 2749-2749.	0.6	0
80	Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial. <i>Blood</i> , 2019, 134, 371-371.	0.6	0
81	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 683-691.	1.3	13
82	Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress. <i>Bone Marrow Transplantation</i> , 2018, 53, 490-494.	1.3	19
83	Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals. <i>Mycoses</i> , 2018, 61, 127-133.	1.8	47
84	Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1197-1207.	1.5	9
85	Diagnosing Invasive Mold Infections: What Is Next. <i>Current Fungal Infection Reports</i> , 2018, 12, 161-169.	0.9	7
86	A Multimodal Imaging Approach Enables <i>In Vivo</i> Assessment of Antifungal Treatment in a Mouse Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	23
87	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3221-3230.	1.3	186
88	Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. <i>Mycoses</i> , 2018, 61, 868-876.	1.8	9
89	Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age. <i>Frontiers in Microbiology</i> , 2018, 9, 661.	1.5	60
90	Genetic deficiency of NOD2 confers resistance to invasive aspergillosis. <i>Nature Communications</i> , 2018, 9, 2636.	5.8	38

#	ARTICLE	IF	CITATIONS
91	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. <i>Microbial Cell</i> , 2018, 5, 300-326.	1.4	81
92	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. <i>JAMA Oncology</i> , 2018, 4, 1245.	3.4	97
93	Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Journal of Hematology and Oncology</i> , 2017, 10, 20.	6.9	43
94	Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. <i>Clinical Infectious Diseases</i> , 2017, 64, 1557-1563.	2.9	39
95	Clinical considerations in the early treatment of invasive mould infections and disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i29-i38.	1.3	11
96	<i>Pneumocystis jirovecii</i> pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipientsâ€™ authorsâ€™ response. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw580.	1.3	13
97	Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium. <i>Acta Clinica Belgica</i> , 2017, 72, 429-433.	0.5	2
98	Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2359-2367.	1.3	65
99	IL-10 overexpression predisposes to invasive aspergillosis by suppressing antifungal immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 867-870.e9.	1.5	37
100	Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	52
101	Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3406-3413.	1.3	58
102	The microbiome-metabolome crosstalk in the pathogenesis of respiratory fungal diseases. <i>Virulence</i> , 2017, 8, 673-684.	1.8	25
103	Evaluation of Bronchoalveolar Lavage Fluid Cytokines as Biomarkers for Invasive Pulmonary Aspergillosis in At-Risk Patients. <i>Frontiers in Microbiology</i> , 2017, 8, 2362.	1.5	54
104	Longitudinal, in vivo assessment of invasive pulmonary aspergillosis in mice by computed tomography and magnetic resonance imaging. <i>Laboratory Investigation</i> , 2016, 96, 692-704.	1.7	28
105	Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 953-963.	0.8	21
106	ECIL guidelines for the diagnosis of <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2386-2396.	1.3	226
107	The current management landscape: aspergillosis: TableÂ1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, ii23-ii29.	1.3	24
108	ECIL guidelines for preventing <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2397-2404.	1.3	211

#	ARTICLE	IF	CITATIONS
109	Pretreatment of Bronchoalveolar Lavage Fluid Samples with SLsolution Leads to False-Negative Aspergillus Galactomannan Levels. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1171-1171.	1.8	3
110	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet, The</i> , 2016, 387, 760-769.	6.3	695
111	Plasmalyte: No Longer a Culprit in Causing False-Positive Galactomannan Test Results. <i>Journal of Clinical Microbiology</i> , 2016, 54, 795-797.	1.8	15
112	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 828-837.	4.6	528
113	Burden of serious fungal infections in Belgium. <i>Mycoses</i> , 2015, 58, 1-5.	1.8	21
114	Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, e102-e105.	1.7	35
115	Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis. <i>PLoS ONE</i> , 2015, 10, e0129022.	1.1	42
116	Nationwide Surveillance of Azole Resistance in Aspergillus Diseases. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4569-4576.	1.4	81
117	Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients. <i>Clinical Therapeutics</i> , 2015, 37, 1317-1328.e2.	1.1	26
118	Invasive Aspergillosis After Kidney Transplant: Case-Control Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 1505-1511.	2.9	38
119	Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2ÂGy TBI or ATG plus 8ÂGy TLI: a phase II randomized study from the Belgian Hematological Society. <i>Journal of Hematology and Oncology</i> , 2015, 8, 4.	6.9	37
120	Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase I Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 720-728.	2.0	56
121	Combination Antifungal Therapy for Invasive Aspergillosis. <i>Annals of Internal Medicine</i> , 2015, 162, 81-89.	2.0	376
122	Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1151-1160.	1.6	15
123	Role of Non-Culture-Based Tests, with an Emphasis on Galactomannan Testing for the Diagnosis of Invasive Aspergillosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 650-661.	0.8	60
124	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. <i>Drug Resistance Updates</i> , 2015, 21-22, 30-40.	6.5	262
125	Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. <i>Clinical Infectious Diseases</i> . 2015, 60, 713-720.	2.9	75
126	Genetic PTX3 Deficiency and Aspergillosis in Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2014, 370, 421-432.	13.9	265



#	ARTICLE	IF	CITATIONS
127	A case with a cytogenetically cryptic variant of the inv(16)(p13q22)/t(16;16)(p13;q22). <i>Cancer Genetics</i> , 2014, 207, 231-232.	0.2	4
128	Impact of Hypoalbuminemia on Voriconazole Pharmacokinetics in Critically Ill Adult Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6782-6789.	1.4	52
129	Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3610-3617.	1.4	79
130	High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3889-3897.	0.8	392
131	Detection of Galactomannan in Bronchoalveolar Lavage Fluid Samples of Patients at Risk for Invasive Pulmonary Aspergillosis: Analytical and Clinical Validity. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1258-1263.	1.8	159
132	The role of antifungal treatment in hematology. <i>Haematologica</i> , 2012, 97, 325-327.	1.7	60
133	Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2330-2336.	1.8	74
134	Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti- $\alpha$ -T-cell globulin ATG-Fresenius. <i>Blood</i> , 2011, 117, 6375-6382.	0.6	281
135	Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. <i>Mycoses</i> , 2011, 54, e449-55.	1.8	49
136	Treatment and timing in invasive mould disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, i37-i43.	1.3	37
137	A Randomized, Double-Blind, Multicenter Study of Caspofungin Versus Liposomal Amphotericin B for Empiric Antifungal Therapy in Pediatric Patients With Persistent Fever and Neutropenia. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 415-420.	1.1	135
138	Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. <i>Blood</i> , 2010, 115, 2586-2591.	0.6	131
139	Reply to Rijnders and Slobbe and to Donnelly and Leeflang. <i>Clinical Infectious Diseases</i> , 2010, 50, 1071-1073.	2.9	5
140	Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. <i>Cancer</i> , 2009, 115, 355-362.	2.0	110
141	Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. <i>Lancet Oncology</i> , The, 2009, 10, 855-864.	5.1	620
142	New therapies for fungal pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 183-190.	1.3	19
143	Early diagnosis and preemptive therapy of pulmonary mold infections in high-risk patients. <i>Current Infectious Disease Reports</i> , 2008, 10, 459-465.	1.3	9
144	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008, 46, 1813-1821.	2.9	4,375

#	ARTICLE	IF	CITATIONS
145	Galactomannan in Bronchoalveolar Lavage Fluid. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 27-34.	2.5	457
146	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clinical Infectious Diseases, 2008, 47, 674-683.	2.9	368
147	Broad-Spectrum Antifungal Prophylaxis in Patients With Cancer at High Risk for Invasive Mold Infections: Counterpoint. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 183-189.	2.3	23
148	Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). Clinical Infectious Diseases, 2007, 44, 1289-1297.	2.9	663
149	Optimization of the Cutoff Value for the Aspergillus Double-Sandwich Enzyme Immunoassay. Clinical Infectious Diseases, 2007, 44, 1329-1336.	2.9	163
150	Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. New England Journal of Medicine, 2007, 356, 348-359.	13.9	1,613
151	PAD Is a Highly Effective Regimen for the Treatment of Patients with Relapsed Refractory Multiple Myeloma.. Blood, 2006, 108, 5095-5095.	0.6	0
152	Early Detection of Toxoplasma Infection by Molecular Monitoring of Toxoplasma gondii in Peripheral Blood Samples after Allogeneic Stem Cell Transplantation. Clinical Infectious Diseases, 2005, 40, 67-78.	2.9	221
153	Galactomannan and Computed Tomography-Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility Study. Clinical Infectious Diseases, 2005, 41, 1242-1250.	2.9	558
154	Fatal pulmonary infection in a leukaemic patient caused by Hormographiella aspergillata. Journal of Medical Microbiology, 2005, 54, 685-688.	0.7	36
155	Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia. New England Journal of Medicine, 2004, 351, 1391-1402.	13.9	868
156	Echinocandins in the Treatment of Aspergillosis. , 0, , 435-443.		0